Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.39 |
| ▸ | SLC6A15 | Q9H2J7 | 4/20 | 0.38 |
| ▸ | FNTA | P49354 | 2/20 | 0.38 |
| ▸ | FNTB | P49356 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTAFR | P25105 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6925309 | 0.85 | F2 (0.47) | F2PRSS1PDK2SLC6A15FNTA | |
| SCHEMBL6921293 | 0.84 | PDK2 (0.50) | F2PDK2CYP1A2CYP2C19KMT2A | |
| SCHEMBL22609096 | 0.69 | PDK2 (0.44) | PDK2CYP1A2CYP2C19KMT2APTAFR | |
| SCHEMBL29395626 | 0.69 | PDK2 (0.44) | PDK2CYP1A2CYP2C19KMT2APTAFR | |
| SCHEMBL22609091 | 0.68 | PDK2 (0.45) | F2PRSS1PDK2CYP1A2CYP2C19 | |
| SCHEMBL29398474 | 0.68 | PDK2 (0.45) | F2PRSS1PDK2CYP1A2CYP2C19 | |
| SCHEMBL6925342 | 0.68 | PDK2 (0.52) | F2PDK2CYP1A2CYP2C19KMT2A | |
| SCHEMBL4023112 | 0.66 | THRB (0.59) | PDK2KMT2A | |
| SCHEMBL9859978 | 0.66 | TDP1 (0.65) | F2PDK2CYP1A2CYP2C19KMT2A | |
| SCHEMBL10345954 | 0.66 | AKR1B1 (0.55) | PDK2KMT2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515011-B2 | Anticoagulants | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| US-20020119992-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002050056-A1 | BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119992-A1 | Thrombin inhibitors | SERPINC1, F2, TFPI | F2 2/4885PRSS1 116/4885PDK2 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.